
## **Grace Christou**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7397863/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring. Leukemia, 2020, 34, 1394-1406.	3.3	23
2	Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation. Transfusion, 2015, 55, 253-258.	0.8	14
3	Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: A systematic review of the literature. Leukemia Research, 2019, 86, 106222.	0.4	12
4	Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials. Transfusion, 2016, 56, 2607-2614.	0.8	10
5	Factors associated with the avoidance of red blood cell transfusion after hematopoietic stem cell transplantation. Transfusion, 2012, 52, 2049-2054.	0.8	9
6	Revised 15-item MDS-specific frailty scale maintains prognostic potential. Leukemia, 2020, 34, 3434-3438.	3.3	8
7	Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia. Leukemia and Lymphoma, 2021, 62, 2295-2297.	0.6	7
8	Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents. Blood, 2019, 134, 4245-4245.	0.6	3
9	The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes. Annals of Hematology, 2022, 101, 1023-1030.	0.8	3
10	A pilot prospective study of the vascular repair response following red cell transfusion in critically ill patients. Transfusion Medicine, 2013, 23, 94-99.	0.5	1
11	Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS. Blood, 2019, 134, 5416-5416.	0.6	1
12	The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes. Blood, 2021, 138, 3064-3064.	0.6	1
13	Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study. Blood, 2020, 136, 41-43.	0.6	1
14	Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2271-2273.	0.6	0
15	Acute Myeloid Leukemia (AML) Treated with Azacitidine: Survival Outcomes for Patients Who Complete More Than Six Cycles Are Similar to High-Risk Myelodysplastic Syndrome/Low Blast Count AML. Blood, 2019, 134, 5156-5156.	0.6	0
16	Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less. Blood, 2019, 134, 3263-3263.	0.6	0
17	High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS. Blood, 2020, 136, 47-48.	0.6	0